In the first half of the 20th century, some women with multiple sclerosis (MS) were advised by their neurologist not to become pregnant, or even to have a therapeutic abortion if they did. 1 However, now it is widely accepted that relapse rate is reduced during pregnancy, at least in the second and third trimester. Furthermore, there is no evidence that pregnancy is associated with negative long-term consequences and some studies have actually suggested beneficial effects. 2, 3 Studies of the effect of pregnancy on MS disease course are confounded by effects of disease severity on the decision of whether to become pregnant. Those with less severe disease reasonably might be expected to choose to become pregnant more often than those with more severe disease due to the fear of not being able take care of a child. An elegant approach to circumventing this confound was undertaken in the study by Ponsonby and colleagues 4 
in this issue of Neurology
® by confining their analysis to persons with a first demyelinating event. In this study of 282 Australian cases and 542 controls, recruited from several sites, they found that the number of pregnancies was inversely associated with the risk of having a first demyelinating event. They concluded that this was consistent with a cumulative effect of pregnancy to reduce the risk of developing MS to one-fourth of the nulliparous risk for those with 3 or more pregnancies, and to one-20th for those with 5 or more pregnancies. Although casecontrol studies are prone to confounding, the authors considered a number of genetic and environmental confounders, including HLA type and sun exposure, among others, and none seemed to explain the observations. Another important conclusion from this work was that prenatal biologic factors in the mother, not postnatal environmental factors that would affect both parents, appeared to be associated with the protection conferred by multiple pregnancies. Evidence in support of this idea was that only mothers, not fathers, showed an effect of the number of family pregnancies on the risk to first demyelinating event. Further, there was no effect of the time since last birth or number of children of various ages in the family. Together, this makes an effect of parental exposure to postnatal environmental factors, such as childhood infections, an unlikely explanation for the main finding of an effect of multiple pregnancies on the risk for first demyelinating event. Rather, a prenatal biologic effect of pregnancy within the mother (hormonal or nonhormonal) is more likely responsible for the decreased risk for first demyelinating event.
The female to male sex bias in MS is increasing (from around 2:1 to almost 3.5:1 within half a century 5 ) due to an increased incidence of MS in females, and not a decreased incidence in males. Environmental factors such as EBV, vitamin D, UV light exposure, or smoking may play a role. 6 As would be suggested by their observations on the favorable effects of pregnancy on the risk of developing demyelinating disease, the authors of the current article suggest that the decrease in the average number of children per mother over the last several decades may be related to the increased incidence of MS in women. Notably, when they assessed established environmental risk factors in their population, these factors did not explain the reduced risk of experiencing a first demyelinating event. Levels of physical activity also did not account for the difference in risk, but further study of this outcome using objective activity monitoring devices, in addition to subjective questionnaires, 7, 8 are warranted, since pregnancy likely has an effect on physical activity.
The study was conducted only in Australia, and the findings will have to be replicated in other countries to be validated. However, the plausibility of the observations of pregnancy on risk of developing demyelinating disease is supported by multiple and consistent observations showing a decrease in MS relapse rate in those who already have MS prior to becoming pregnant. 
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pregnancies on relapse rate translates into a favorable effect on long-term evolution of disability. 10 Several studies have addressed the effect of pregnancy on disability; while there were no reported short-term effects of pregnancy on disability, the long-term effects varied from little to no effect to beneficial long-term effects.
With the body of evidence supporting favorable effects of pregnancy on both the short-term course of MS and risk of developing demyelinating disease, 2, 3 the need for research into the underlying mechanism and therapeutic approaches mimicking the pregnancy milieu is even more compelling. Estriol, the major estrogen of pregnancy, reduced brainenhancing lesions in a pilot clinical trial 11 and induced a favorable alteration in mononuclear cell cytokine production. 12 Studies of estrogen treatment in an animal model of MS have shown both antiinflammatory as well as direct neuroprotective effects. 13 A larger, placebo-controlled, multicenter clinical trial of estriol treatment in the United States (http://www.clinicaltrials.gov/ct2/show/NCT00 451204?termϭestriolϩANDϩmultipleϩsclerosis& rankϭ1) is now fully enrolled. There is an ongoing trial of estrogen and progestin treatment in Europe to prevent the precipitous drop in these hormones postpartum with the goal of preventing relapses in the first 3 to 6 months after delivery.
Based on another study by a French consortium, also published in this issue of Neurology, 14 which is the first to address effects of pregnancy on neuromyelitis optica (NMO), this advice can only be partially extended to counseling those with other inflammatory CNS diseases such as NMO. NMO is an astrocytopathy resulting from antibody-mediated targeting of the major CNS water channel, aquaporin-4. Some treatments that are effective for MS are either ineffective or potentially deleterious to patients with NMO. 15 The consortium evaluated the frequency of relapses in a population of patients with NMO. Similar to results of a previous study by the same group in MS, there was a trend for a lower frequency of attacks in the first 2 trimesters, with an increase in the first postpartum trimester in pregnant patients with NMO. In contrast, during the third trimester the attack rate rose in individuals with NMO whereas it declined in MS, although neither the differences among any of the pregnancy-defined epochs for patients with NMO nor the differences between patients with NMO and patients with MS for any given epoch were significant. Given that the average age at onset of NMO is higher than in MS, predictably, only a relatively few patients with NMO became pregnant subsequent to or within 1 year preceding a diagnosis of NMO (n ϭ 20) and were accordingly informative. Statistical significance of an effect of pregnancy on NMO or differences between NMO and MS were not established and will require confirmation in other studies. However, the results provide some reassurance to women with NMO who are considering pregnancy that there is not a major increase in attack rate during pregnancy and the increase in attack risk postpartum is transient.
Both MS and NMO are complex immunologic diseases with multiple interacting effector mechanisms. Whether the observations regarding the effects of pregnancy on NMO and MS provide insights into differences in immunopathogenesis remains a question to be resolved in the future.
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